Battery materials company NOVONIX has encountered a significant setback in its strategic efforts to establish a domestic US supply chain. The US International Trade Commission (ITC) delivered a ruling in mid-March that rejected the imposition of substantial anti-dumping and countervailing duties on Chinese anode material imports. This decision alters the competitive landscape for the specialist producer of synthetic graphite.
US Trade Commission Rejects Tariff Proposal
The ITC’s determination effectively removes potential import duties of at least 160% that had been previously proposed by the US Department of Commerce. In its finding, the Commission concluded that imports from China do not materially retard the establishment of a domestic US industry. For NOVONIX, which has been banking on a protected market to build its North American operations, this represents a notable disappointment, diminishing the anticipated pricing advantage over cheaper Chinese imports.
A layer of protection remains, however. Due to existing tariffs and a temporary special levy, the total current duty burden on Chinese material stands at 35%. Market observers note that this additional safeguard is temporary in nature.
Strategic Refocus on Core Production
In response to this challenging environment, NOVONIX is streamlining its business portfolio. Following the sale of a mining project last year, the company now plans to divest its Battery Technology Solutions (BTS) division. The strategic objective is a complete focus on synthetic graphite production at its facilities in Tennessee.
Should investors sell immediately? Or is it worth buying NOVONIX?
The company aims to position itself as a cornerstone of the US battery supply chain by developing its Riverside and Enterprise South sites in Chattanooga. Combined, these locations are projected to achieve an annual production capacity exceeding 50,000 tonnes, a move designed to reduce reliance on global supply networks.
Nasdaq Listing Compliance Adds to Challenges
Beyond operational headwinds, NOVONIX is confronting regulatory pressures in the capital markets. The company received a deficiency notice from the Nasdaq exchange after the price of its American Depositary Receipts (ADRs) closed below the $1.00 threshold for 30 consecutive business days.
To avoid delisting, NOVONIX now has 180 calendar days to regain compliance by sustaining a share price above $1.00 for a minimum of ten consecutive business days. Despite a gain of over 10% in today’s trading to €0.17, the situation remains tense. Since the start of the year, the company’s shares have declined in value by approximately 28%.
Shareholders are looking ahead to the Annual General Meeting, scheduled for April 15, 2026, in Brisbane. The event is expected to provide further details on the progress of the BTS divestment negotiations and concrete updates on the production scaling efforts in Chattanooga.
Ad
NOVONIX Stock: Buy or Sell?! New NOVONIX Analysis from April 2 delivers the answer:
The latest NOVONIX figures speak for themselves: Urgent action needed for NOVONIX investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 2.
NOVONIX: Buy or sell? Read more here...
